Physician profile
Mark A Malek
NPI 1962841346
$1,512.20
in general payments reported to CMS, 2019-2025
18 companies · $20.74 in 2025
The $20.74 reported for 2025 was less than what a typical Public Health & General Preventive Medicine provider received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $140 · 2021: $55.21 · 2022: $118 · 2023: $454 · 2024: $187 · 2025: $20.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.14 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.13 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $156.84 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $121.41 | 2022-2024 | Freestyle Libre 3 |
| Allergan, INC. | $107.01 | 2019 | |
| Lilly USA, LLC | $102.82 | 2019-2024 | Mounjaro |
| Pfizer INC. | $90.37 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $68.79 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $57.55 | 2022-2023 | |
| Galderma Laboratories, L.P. | $55.00 | 2020-2023 | |
| Amarin Pharma, INC. | $53.84 | 2019 | |
| Amgen INC. | $50.81 | 2019 | |
| Astellas Pharma US INC | $47.17 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.80 | 2019 | |
| Dexcom, INC. | $22.67 | 2024 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.46 | 2023 | |
| Idorsia Pharmaceuticals US INC | $20.74 | 2024 | Quviviq |
| Smith+Nephew, INC. | $17.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.